This grant, offered by the National Institutes of Health (NIH), aims to comprehensively validate novel therapeutic target candidates for Alzheimer’s Disease-Related Dementias (ADRDs). The purpose is to de-risk subsequent translational research and accelerate new therapies for conditions like FTD, Lewy body dementias, Parkinson disease dementia, and vascular dementias. Applicants must propose targets identified from human tissue or genetic data. The program proceeds in two phases: an initial phase (R61) supports developing customized technologies and models to modulate target expression and monitor consequences. A second phase (R33) focuses on reproducibly measuring the target modulation’s impact across collaborating laboratories, adhering to NIH rigor and reproducibility guidelines. Substantial collaboration between independent laboratories is required.
Opportunity ID: 342685
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-NS-22-055 |
| Funding Opportunity Title: | Functional Target Validation for Alzheimer’s Disease-Related Dementias (ADRDs) (R61/R33 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.853 — Extramural Research Programs in the Neurosciences and Neurological Disorders |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jul 22, 2022 |
| Last Updated Date: | Jul 22, 2022 |
| Original Closing Date for Applications: | Nov 08, 2022 |
| Current Closing Date for Applications: | Nov 08, 2022 |
| Archive Date: | Dec 14, 2022 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Special district governments Native American tribal governments (Federally recognized) City or township governments Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts For profit organizations other than small businesses County governments Public and State controlled institutions of higher education Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled “Additional Information on Eligibility” for clarification) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments Small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This FOA invites applications that propose the comprehensive functional validation of newly identified therapeutic target candidates for Alzheimer’s Disease-Related Dementias (ADRDs). This FOA seeks to promote critical target validation approaches to help de-risk subsequent translational research and accelerate the advancement of novel therapies for ADRD. Target(s) or molecular pathway(s) to be considered for validation must have been already identified using tissue expression or genetic data generated in human samples. In its initial phase, this FOA provided support for up to two years (R61 stage) for the development of customized technologies, models, and protocols to modulate the expression or activity of target candidate(s) in cells or tissues and monitor their functional biological consequences in in vitro or in vivo disease models. Upon demonstration of technical feasibilities, a second phase (R33 stage) will carefully and reproducibly measure and cross-validate the impact of the target modulation in different modalities across collaborating laboratories using the NIH rigor and reproducibility guidelines. Applicants responding to this FOA must address objectives for both the UG3 and UH3 phases and are expected to have a substantial collaborative effort between independents laboratories. This FOA is not specific for any one or group within the ADRD spectrum of disorders. Disorders covered in these applications are frontotemporal degeneration (FTD), Lewy body dementias (LBD) (including dementia with Lewy bodies (DLB)), Parkinson disease dementia (PDD), vascular contributions to cognitive impairment and dementia (VCID), mixed dementias including the associated diagnostic challenges of multiples etiology dementias (MED). |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-055.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
OERWebmaster03@od.nih.gov Email:OERWebmaster03@od.nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster OERWebmaster03@od.nih.gov Email: OERWebmaster03@od.nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-G | Use for due dates on or after January 25, 2022 | PKG00276140 | Oct 07, 2022 | Nov 08, 2022 | View |
Package 1
Mandatory forms
342685 RR_SF424_5_0-5.0.pdf
342685 PHS398_CoverPageSupplement_5_0-5.0.pdf
342685 RR_OtherProjectInfo_1_4-1.4.pdf
342685 PerformanceSite_4_0-4.0.pdf
342685 RR_KeyPersonExpanded_4_0-4.0.pdf
342685 RR_Budget_3_0-3.0.pdf
342685 PHS398_ResearchPlan_4_0-4.0.pdf
342685 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
342685 RR_SubawardBudget30_3_0-3.0.pdf
342685 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
